Pre-menopausal women with advanced breast cancer: adding Ribociclib to first-line endocrine therapy significantly improves survival
The randomized phase III MONALEESA-7 trial found that adding Ribociclib ( Kisqali ) to standard-of-care endocrine therapy has significantly improved overall survival for premenopausal women with advan ...
read article